Sorry, you need to enable JavaScript to visit this website.

PF-06804103 Dose Escalation in HER2 Positive and Negative Solid Tumors

PF-06804103 Dose Escalation in HER2 Positive and Negative Solid Tumors. A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors.

Category & Conditions: Cancer
Medicine: PF-06804103
ClinicalTrials.gov Identifier (NCT): NCT03284723
Protocol ID: C0541001
    Share
PrintDownload
Open Plain Language Summary Result: Click here